Renalytix AI (GB:RENX) has released an update.
Renalytix AI has announced its intention to appeal the Nasdaq’s delisting determination after failing to meet the minimum bid price and market value requirements for continued listing. The company’s American Depositary Shares will remain on the Nasdaq Global Market pending the appeal’s outcome, with no guarantee of compliance restoration. Potential delisting raises concerns about the impact on stock liquidity and the company’s ability to raise capital.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
